![]() ![]() However, the response of NSCLC patients to TKI therapy seriously depends on the mutant status in exons 18–21 of EGFR, which code for the tyrosine kinase domain. Along with the comprehensive molecular profiling of cancer-related genes, the insight into cancer treatment has been revolutionized and targeting the epidermal growth factor receptor ( EGFR) through the tyrosine kinase inhibitor (TKI) has been regarded as an effective therapeutic strategy for NSCLC from a clinical oncology perspective. Lung cancer is a primary malignant tumor with a high incidence and mortality rate worldwide non-small cell lung cancer (NSCLC) is the dominating subtype of lung cancer, which accounts for approximately 85% of these cases. ![]() Thus, we propose that this straightforward strategy may serve as a promising tool for NSCLC diagnosis in clinical practice. In addition, this method can be easily extended for other genetic information decoding using a tailor-made primer set. As a demonstration, L858R, the primary point mutation for the sensitization of EGFR, has been accurately decoded using this assay with highly heterogeneous cancerous tissue. Moreover, complex operation and time-consuming data processing, as well as the aerosol contamination, are avoided owing to the whole process for intelligent genetic decoding being performed in a sealed tube. ![]() By optimizing the component and condition of the nucleic acid amplification system, a sensitive and specific distinguishability is achieved for tracing target variant (60 copies, 0.1%) identification under a strong interferential background within 40 min. In this research, a one-pot assay for EGFR identification is established by combining a loop-mediated isothermal amplification and amplification refractory mutation system. Hence, the individualized therapeutic strategy has highlighted the demand for a simple, fast, and intelligent strategy for the genetic decoding of EGFR to cater to the popularization of precision medicine. Targeting the sensitized epidermal growth factor receptor ( EGFR) caused by gene mutation through the tyrosine kinase inhibitor is an effective therapeutic strategy for NSCLC. Non-small cell lung cancer (NSCLC) is a major cause of cancer-related deaths around the world. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |